(BFM Stock Exchange) – The action of the Danish group is suffering this Tuesday, penalized by the good clinical results of Orforglipron, molecule of its American rival Eli Lilly and intended for the treatment of obesity and type 2 diabetes.

Difficult session for Novo Nordisk. The title of the Danish pharmaceutical giant Novo Nordisk, known for Ozempic and Wegovy, its treatments for diabetes and weight loss, fell strongly on Tuesday after the announcement of clinical trials successful by its competitor Eli Lilly.

Novo Nordisk, which is among the first European stock market capitalizations, lost 7.7% in the early afternoon on the Copenhagen Stock Exchange after Easter weekend.

This fall follows the announcement Thursday by the US laboratory Eli Lilly of encouraging clinical trials for its treatment against type 2 diabetes and obesity, orforglipron, which made its action jump by 14.30%.

“A negative element”

In a note devoted to Eli Lilly, Bank of America judged that these results constituted “with the best possible scenario – with regard to weight loss, blood sugar, tolerability and security”.

“In summary, the data largely corresponded to our expectations, but nevertheless represent a minor negative element for Novo in our opinion, although it is certainly not an element that changes the thesis in the context of current levels and feeling, which reflect a deep concern about the prospects for growth for injectable novo assets”, comments, this Tuesday, Deutsche Bank.

In February, Novo Nordisk had published a net profit up 21%, exceeding 100 billion crowns (13.4 billion euros), while turnover established at 290.4 billion crowns, up 25%.

A real bestseller with a turnover representing 41% of its sales, the Ozempic is the world number one of antidiabetics, causing all of social networks for its weight loss properties.

Novo Nordisk launched the Wegovy in the United States in 2021.

(With AFP)